Contact this trialFirst, we need to learn more about you.
DNA Methyltransferase Inhibitor
Guadecitabine + Donor Lymphocytes for Leukemia Relapse After Transplant
Recruiting1 awardPhase 2
Houston, Texas
This trial studies how well guadecitabine works in patients with AML or MDS who relapsed after a stem cell transplant. Guadecitabine is a new type of treatment similar to other drugs that have been effective in treating these conditions. The treatment involves injections of guadecitabine and possibly additional help from donor cells. The drug aims to stop cancer growth and prevent harmful immune reactions, while the donor cells help the immune system fight cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service